Navigation Links
Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
Date:1/26/2012

TARRYTOWN, N.Y., Jan. 26, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2011 financial and operating results on Thursday, February 16, 2012, before the U.S. financial markets open.  The Company will host a conference call at 8:30 AM EST that day.

Live audio of the conference call will be webcast online simultaneously.  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at www.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.  

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA™ (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information:   

 Manisha Narasimhan, Ph.D.

Peter DworkinInvestor Relations

Corporate Communications914-847-5126

914.847.764Manisha.narasimhan@regeneron.com

peter.dworkin@regeneron.com 


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
2. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
3. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
4. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
5. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
6. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
7. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
8. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
9. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
10. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
11. Regeneron Reports Second Quarter 2011 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Tenn. , March 23, 2017  Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... announced Definitive Financing Commitment Term Sheet (the "Definitive ... a group of the Company,s stockholders, who are ... Group" in a Form 8-K filed with the ...
(Date:3/23/2017)... 23, 2017 The key factors driving ... diabetic population, accelerating economic growth and increasing healthcare expenditure. Some ... higher life expectancy of ESRD patients, rising demand for home ... the expansion of the market is hindered by high treatment ... ...
(Date:3/23/2017)... 23, 2017 As a result of ... the prevalence of allergic diseases, cutting edge developments ... revolutionising the ways in which pharmaceutical and biotech ... promises to be both a high quality meeting ... interest groups, immunologists, research scholars and doctors. The ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... Digital Scientists, a software innovation lab specializing in web design and ... Carolina location. The lab has set up shop at the renowned NEXT Innovation ... Carolina clients for years from our office here in Atlanta,” explains Digital Scientists’ CEO, ...
(Date:3/24/2017)... Lake Orion, MI (PRWEB) , ... March 24, ... ... providing insurance assistance, financial planning, and related services to families and business owners ... charity initiative aimed at feeding regional families struggling with financial difficulties. , The ...
(Date:3/24/2017)... CA (PRWEB) , ... March 24, 2017 , ... ... on two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, ... Creating the Administrative Record, The majority of cases litigated under ERISA involve claims ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
Breaking Medicine News(10 mins):